dla pacjentów i lekarzy
Onkologia - aktualności medyczne dla lekarzy
PZWL zaprasza na kolejną edycję wirtualnej akademii. Wybitni specjaliści omówią najbardziej palące tematy leczenia wspomagającego w onkologii. Wydarzenie jest bezpłatne i przeznaczone dla lekarzy wszystkich specjalizacji uczestniczących w procesie leczenia chorych na nowotwory.
Despite adjustment for previously unmeasured confounders, breast-conserving surgery with radiotherapy yielded better survival than mastectomy irrespective of radiotherapy. If both interventions are valid options, mastectomy should not be regarded as equal to breast conservation.
Phase III study results point to noninferiority of acalabrutinib, while it provides improved safety in patients with previously treated chronic lymphocytic leukaemia.
FDA approved pembrolizumab for high-risk, early-stage, triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. KEYNOTE-522 study was the basis for approval in the neoadjuvant and adjuvant setting.
Rak wątroby – nowa terapia pozwala na leczenie chirurgiczne pacjentów, którzy według obecnych kryteriów zostali uznani za nieuleczalnie chorych
Połączenie kabozantynibu, leku będącego inhibitorem kinazy, oraz stosowanego w immunoterapii niwolumabu, może umożliwić leczenie chirurgiczne u niektórych pacjentów z rakiem wątroby, którzy ze względu na stopień zaawansowania nowotworu normalnie zostaliby uznani za przypadki nieoperacyjne.
Combined hormone/radiotherapy treatment improves event-free and disease-free survival in patients with localised intermediate risk prostate cancer
Adding ADT to EBRT to patients with localised intermediate risk prostate cancer significantly increases their event-free survival (EFS)1 and disease-free survival (DFS)2, and these effects are still evident after 12 years of median follow-up, say the investigators in the latest results from an EORTC trial published in The Journal of Clinical Oncology this week.
In light of findings from multiple recent clinical trials in HER2-negative metastatic breast cancer, ASCO has revised its treatment recommendations to inform more evidence-based care for metastatic breast cancer. This guideline update provides important clinical guidance about the new use of immune checkpoint inhibitors, antibody-drug conjugates, and PARP inhibitors.
A recently updated ASCO guideline offers both new and revised guidance on the treatment of hormone receptor (HR)–positive, HER2-negative metastatic breast cancer. Update encourages use of CDK4/6 inhibitors, alpelisib.
EMA adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Imatinib Koanaa, intended for the treatment of leukaemia and gastrointestinal stromal tumours.
During the last year, a flurry of clinical trial data have provided greater insight into mechanisms of novel therapies for breast cancer management. Some of these data, including abstracts presented during the 2021 ASCO Annual Meeting, have wide practice-changing implications in triple-negative breast cancer (TNBC) or patients with high-risk, HER2-negative, early-stage disease.
Advances in Targeted Therapies, Immunotherapy Improve Treatment Options for Patients With Lung Cancer
Major advances in lung cancer announced during the 2021 ASCO Annual Meeting follow a year of stunning progress in targeted therapies and immunotherapy that has energized the field. We have seen more progress in the development of targeted therapies and improvement in the lives of our patients in the last 5 years than over the past 25 years in the lung cancer space.
Recent analysis of large case-control data sets allows for the assessment of many additional genes associated with breast cancer, including ATM, BARD1, CDH1, CHEK2, NF1, PALB2, PTEN, RAD51C, and RAD51D, and offers compelling insights on hereditary breast cancer genetics.
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
Clinical trial evidence suggests that nivolumab plus ipilimumab may extend how long people live. The most relevant trial did not directly compare nivolumab plus ipilimumab with usual treatments, but indirect comparisons suggest that it substantially increases how long it takes for the cancer to get worse and how long people live.
Healthy lifestyle factors such as abstinence from smoking and drinking, low body mass index, and exercise correlated with decreased cancer incidence, even in individuals with a high genetic risk, according to results of a study published in Cancer Research, a journal of the American Association for Cancer Research.
Updated worldwide estimates of cancers associated with alcohol consumption stratified by gender, tumour localisation and country indicate causal relation of alcohol with a substantial number of cancer cases that could potentially be avoided. Among all new cancers in 2020, 4.1% were related to alcohol consumption.
W dniu 3.09.2021 rozpocznie się dwudniowa konferencja „Rak piersi – aktualne zalecenia w zakresie leczenia miejscowego i programów lekowych”. Sesja pierwsza będzie poświęcona problemom radioterapii po rekonstrukcji piersi. Organizatorzy zachęcają polskie ośrodki chirurgiczne i radioterapeutyczne do podzielenia się swoimi doświadczeniami w tym zakresie.
High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer
The higher radiotherapy dose of 60 Gy resulted in a substantial survival improvement compared with 45 Gy, without increased toxicity, suggesting that twice-daily thoracic radiotherapy of 60 Gy is an alternative to existing schedules.
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of radiation therapy to treat adult patients with soft tissue sarcoma (STS).
Women Over Age 65 Years with Pathogenic Variants in Cancer Predisposition Genes Continue to Be at Increased Risk of Breast Cancer
Women over age 65 years with pathogenic variants in cancer predisposition genes rarely benefit from hereditary cancer genetic testing. A population-based study examined whether women in this age category may qualify for clinical genetic testing and magnetic resonance imaging (MRI) screening.
Withdrawal concerns the application to extend the use of atezolizumab to include the treatment of early or locally advanced triple-negative breast cancer.
FDA approved pembrolizumab in combination with lenvatinib for patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
Some people who have a rare form of bile duct cancer are set to benefit from life-extending treatment pemigatinib after NICE published final draft guidance today (22nd July 2021).
Prefrail and Frail Young Adult Survivors of Childhood Cancers Experience Significant Neurocognitive Decline
Over a 5-year follow-up interval, frail young adult survivors of childhood cancers experienced significantly larger declines than nonfrail survivors in memory, attention, processing speed, and executive function domains.
Pembrolizumab Demonstrates Robust, Durable Antitumour Activity and Promising Survival in Advanced Cutaneous Squamous Cell Carcinoma
The results of the second interim analysis of the KEYNOTE-629 study that include initial data for the locally advanced cohort and updated data for the recurrent/metastatic cohort of patients with cutaneous squamous cell carcinoma confirm durable pembrolizumab antitumour activity and promising survival in both settings.
How the CROWN Study Affects Treatment of Patients With ALK-Positive Metastatic Non–Small Cell Lung Cancer
Based on data from the CROWN study, lorlatinib is now approved by the U.S. Food and Drug Administration for use in patients with newly diagnosed advanced ALK-positive non–small cell lung cancer (NSCLC), joining ceritinib, alectinib, brigatinib, and ensartinib.
Prognostic Significance of Lynch-like versus Sporadic MSI-H Endometrial Cancer Treated With Pembrolizumab
In a single-arm, open-label phase II study, the investigators evaluated pembrolizumab in patients with recurrent mismatch repair deficient (dMMR) and/or microsatellite instability-high (MSI-H) endometrial cancer.
Chemoradiotherapy and MRI-based IGABT result in effective and stable long-term local control across all stages of locally advanced cervical cancer, with a limited severe morbidity per organ. These results represent a positive breakthrough in the treatment of locally advanced cervical cancer, which might be used as a benchmark for clinical practice and all future studies.
FDA approved belumosudil, a kinase inhibitor, for adult and paediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.
Hypogammaglobulinemia and Sars-CoV-2 Viraemia Determine COVID-19 Severity in Patients with Haematological Malignancies
Team of scientists investigated clinical factors associated with higher risk for severe COVID-19 in patients with haematological malignancies. They wrote in the Annals of Oncology that the coronavirus infection itself, rather than cytokine storm, lead to severe and lethal COVID-19 in these patients.
Ficlatuzumab Plus Chemotherapy Shows Promise for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia
The investigational therapeutic ficlatuzumab in combination with chemotherapy showed signs of clinical efficacy in patients with relapsed/refractory acute myeloid leukemia, according to results published in Blood Cancer Discovery, a journal of the American Association for Cancer Research.
40% of cancers are preventable. For this reason, both the European Union and World Health Organization actively support countries in policy propositions that can assist in addressing modifiable cancer risks. But are there opportunities to move faster and go further? A new report by the European Cancer Organisation suggests so.
Combined MRI-directed and Standard Biopsy in Men With Elevated PSA and Positive Results on MRI Non-inferior to Standard Biopsy
In a study of population-based screening by invitation, the results showed that among men with elevated PSA levels, combined biopsy performed only in men who had positive results on magnetic resonance imaging (MRI) was non-inferior to standard biopsy for detecting clinically significant prostate cancer.
The National Cancer Institute definition of survivorship stipulates that a cancer survivor as an individual is considered to be a survivor from the time of diagnosis to the end of life. It acknowledges that cancer treatment and its consequences do not end when a specific cancer-directed therapy ends, while also implying that the road to recovery and adaptation can begin as soon as a patient is diagnosed.
Approximately 50% of patients with muscle-invasive urothelial carcinoma develop metastatic disease within 2 years of radical cystectomy alone, which commonly leads to death.1 Clinicians and researchers have strived for decades to improve this metastasis rate by integrating systemic therapy.
Incremental Progress, Reassuring Results Featured Among Gynecologic Malignancies Research at 2021 ASCO Annual Meeting
Although several studies in gynecologic malignancies have potential to change practice down the road, the OUTBACK trial on adjuvant chemotherapy in cervical cancer was the most impactful work presented at this year's Annual Meeting.
Cabazitaxel has proven benefit as a second-line therapy for patients with mCRPC who have progressed rapidly (< 12 months) through prior ASTI treatment. Immunotherapy for prostate cancer remains under clinical investigation, with pembrolizumab indicated only for prostate cancers with MSI-high or TMB-high molecular phenotypes.
Adjuvant Platinum Chemotherapy Does Not Improve Outcomes in Patients With Triple-Negative Breast Cancer With Residual Disease
Recently published findings from the phase III EA1131 trial show that, compared to capecitabine, adjuvant platinum chemotherapy does not improve outcomes in patients with triple-negative breast cancer (TNBC) with residual disease.
FDA Approves Daratumumab and Hyaluronidase-fihj With Pomalidomide and Dexamethasone for Multiple Myeloma
FDA approved daratumumab and hyaluronidase-fihj in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor.
FDA Approves Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn for Acute Lymphoblastic Leukaemia and Lymphoblastic Lymphoma
FDA approved asparaginase erwinia chrysanthemi (recombinant)-rywn as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL) in adult and paediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase.
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck
The primary objective of prolonging progression-free survival with avelumab plus chemoradiotherapy followed by avelumab maintenance in patients with locally advanced squamous cell carcinoma of the head and neck was not met. These findings may help inform the design of future trials investigating the combination of immune checkpoint inhibitors plus CRT.
FDA Grants Regular Approval to Enfortumab Vedotin-ejfv for Locally Advanced or Metastatic Urothelial Cancer
FDA approved enfortumab vedotin-ejfv, a Nectin-4-directed antibody and microtubule inhibitor conjugate, for adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD1 or PD-L1 inhibitor and platinum-containing chemotherapy, or are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.
Analysis of the Gut Microbiome Provides Clues to Survival Following Nivolumab Therapy for Advanced Gastric Cancer
A team of investigators from Japan detected several genomic pathways and bacterial genera in the pre-treatment gut microbiome of patients with advanced gastric cancer that were significantly associated with survival times following treatment with nivolumab. These findings were presented at the ESMO World Congress on Gastrointestinal Cancer 2021.
Longer-Term Follow-Up of Breast Cancer Trials Add Further Insight Into Efficacy of Promising Combination Regimens
Several pivotal trials in recent years have contributed to greater understanding of the durability and efficacy of certain novel combination regimens for breast cancer. Long-term follow-up data from three trials HER2CLIMB, PALOMA-3, and MONALEESA-3—further established these therapeutic regimens as potentially important components of clinical care.
Research has repeatedly shown that geriatric assessment, toxicity risk tools, comanagement strategies, and multidisciplinary care models are more accurate than traditional performance status metrics to evaluate older patients with cancer.
Adding Avelumab to Preoperative Chemoradiotherapy Provides Promising Anti-Tumour Activity in Locally Advanced Rectal Cancer
Many patients with locally advanced rectal cancer receiving a preoperative regimen of standard chemoradiotherapy plus avelumab achieved pathological complete response and the majority of patients showed a major pathological response, according to findings from a phase II AVANA study presented at the ESMO World Congress on Gastrointestinal Cancer 2021.
It is intended for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem-cell transplant (ASCT).
Enzalutamide plus androgen deprivation therapy (ADT) is recommended, within its marketing authorisation, as an option for treating hormone-sensitive metastatic prostate cancer in adults.
Nivolumab is recommended as an option for treating locally advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC) in adults after chemotherapy, only if: their tumours are PD-L1 positive, and it is stopped at 2 years of uninterrupted treatment, or earlier if their disease progresses, and they have not had a PD-1 or PD-L1 inhibitor before.
Expression of AR-regulated Genes in CTCs Is Prognostic for Survival and Radiographic Progression in Metastatic Prostate Cancer
07.07 Novel liquid biopsy technology to collect mRNA from circulating tumour cells (CTCs) may be used to measure expression of androgen receptor (AR) splice variants, AR targets, and neuroendocrine prostate cancer markers.
The management of acquired resistance to EGFR-mutated non–small cell lung cancer (NSCLC) has undergone significant change since osimertinib was approved by FDA for first-line treatment of the most common EGFR-activating mutations, EGFR E19del and L858R, in December 2020.
At least 42% of newly diagnosed cancers in the United States are potentially avoidable because they are attributable to lifestyle factors such as smoking, alcohol consumption, poor nutrition, and lack of physical activity.
Age is perhaps the most significant risk factor for cancer incidence. With increased longevity of the population, early detection, and more effective therapies, the number of older patients with cancer and survivors of cancer will continue to rise.
20 listopada 2021 roku, w sobotę, odbędzie się konferencja „UroScrabble”. Wydarzenie kierowane jest do urologów, onkologów, nefrologów, lekarzy rodzinnych oraz wszystkich specjalistów zainteresowanych tematyką wyszczególnioną w programie.
Trastuzumab deruxtecan demonstrated clinically meaningful benefit across specific subgroups of patients with HER2-positive and HER2-low advanced gastric cancer according to findings from a post-hoc exploratory biomarker analysis presented at the ESMO World Congress on Gastrointestinal Cancer 2021.
Radiotherapy plays an important role in breast cancer management. After breast-conserving surgery, radiotherapy reduces the probability of recurrence and improves overall survival. Adjuvant whole-breast irradiation (WBI) was previously delivered in daily treatments, given over five–six weeks. These treatments, coupled with other multidisciplinary advances such as increasing the use of systemic therapy, yielded outstanding outcomes.
First-Line Encorafenib, Binimetinib, and Cetuximab Combination Provides Clinical Benefit and Manageable Safety in BRAF V600E–Mutated mCRC
Almost half of patients with previously untreated BRAF V600E–mutated metastatic colorectal cancer (mCRC), who generally have a poorer prognosis, demonstrated response and 88% showed disease control following combination treatment with encorafenib, binimetinib, and cetuximab.
Preoperative ctDNA Levels Are Detectable in the Majority of Patients with Resectable Colorectal Cancer
A team of investigators in Japan used a personalised assay for circulating tumour DNA (ctDNA) levels in plasma to monitor minimal residual disease following surgery in patients with resectable colorectal cancer. Their subgroup analysis found statistically significant associations between ctDNA levels and the pathological disease stage.
ctDNA Analysis is Feasible for Detection of Minimal Residual Disease After Treatment Across a Variety of MMRd Tumour Types
Circulating tumour DNA analysis is a feasible tumour agnostic approach for evaluation of the efficacy of checkpoint blockade in patients at high risk of recurrence.
Characterisation of KRAS, Including KRAS G12C, Mutations in Gastrointestinal and Metastatic Colorectal Cancer
Three studies delineating the prevalence of KRAS mutations in gastrointestinal and colorectal cancer, with specific focus on the KRAS G12C mutation, and an evaluation of patient outcomes according to the mutation status were presented at the ESMO World Congress on Gastrointestinal Cancer 2021.
Over the past decade, immunotherapies have transformed the treatment of patients with certain aggressive cancers, including lung and melanoma. However, less progress has been made in difficult-to-treat brain tumors. But data presented during the 2021 ASCO Annual Meeting offered promising findings for patients with unique subtypes of brain tumors.
New Research Exploring the Role of Pembrolizumab in Locally Advanced Oral Cancers Warrants Further Investigation
The incidence of oral cancer is increasing in young adults and in adults who have never smoked, representing a high unmet need. New research on neoadjuvant pembrolizumab suggests that immunotherapy may play a promising role in locally advanced oral cancers.
Obese patients with colorectal cancer receive lower cumulative doses of adjuvant chemotherapy, relative to their body surface area (BSA), than non-obese patients, show results from a large meta-analysis reported at the ESMO World Congress on Gastrointestinal Cancer 2021.
Doctors and patients are being advised to reduce unnecessary antibiotic use following new data suggesting that these medicines may increase the risk of cancer of the large intestine (colon), especially in people under 50 years.
The Investigational PD1 Antibody, Tislelizumab, Shows Promise in Patients With Unresectable Hepatocellular Carcinoma
A novel anti-PD1 agent, tislelizumab, is under development for the treatment of patients with solid tumours and has demonstrated clinical benefit in unresectable hepatocellular carcinoma (HCC), according to findings from a phase II study presented at the ESMO World Congress on Gastrointestinal Cancer 2021.
New indication concerns adjuvant treatment of oesophageal or gastro-oesophageal junction cancer with residual disease following prior neoadjuvant chemoradiotherapy.
Sexual health problems, including genital symptoms, changes in sexual response, and psychosocial issues, are prevalent in women with cancer, yet these patients are rarely asked about their sexual concerns. Oncology teams must commit to assessing and addressing sexual health, and multiple resources are available for the busy professional.
The ASCO Annual Meeting Plenary Session consistently features some of the most important treatment advances that have occurred over the past year across the broad spectrum of cancers. We asked experts to share their thoughts on the five randomized phase III clinical trials presented during the 2021 Session and how the results of these trials are likely to influence clinical practice.
Ovarian cancer carries a heavy morbidity and mortality burden, particularly in settings and regions of the globe that feature significant limitations in health care resources. Given that ovarian cancer is more lethal than breast cancer, clinicians in resource-limited areas require guidance on the appropriate assessment and treatment of patients with this disease.
On June 30, FDA approved Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients who are allergic to the E. coli-derived asparaginase products used most commonly for treatment.
Individualised Nutritional Support Reduce the Risk of Mortality in Cancer Patients with Increased Nutritional Risk
Among 506 hospitalised patients with cancer at nutritional risk, individualised nutritional support reduced the risk for mortality as compared to standard hospital food. The findings from a preplanned secondary analysis of a prospective, randomised, multicentre Effect of early nutritional support on Frailty, Functional Outcomes and Recovery of malnourished medical inpatients Trial (EFFORT).
European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre Partner to Address Treatment Gap for Stage 2 Melanoma Patients
European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre today announced a strategic partnership in support of patients with resected Stage 2 BRAF-mutant melanoma. The partnership includes the planning, design and execution of a large Phase 3 study investigating the use of BRAF and MEK targeted therapies to reduce the risk of relapse in this patient population.
On 24 June 2021, EMA adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product idecabtagene vicleucel (Abecma), intended for the treatment of relapsed and refractory multiple myeloma.
28.06 A phase I/II study of TK216 in patients with R/R Ewing sarcoma demonstrated durable responses among heavily pretreated patients. Data from the SPEARHEAD-1 trial showed the safety and efficacy of afamitresgene autoleucel in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.
Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes
The long-term results of this trial confirmed the higher rate of ipsilateral breast tumour recurrence (IBTR) in the ELIOT (electron intraoperative radiotherapy) group than in the whole-breast irradiation group, without any differences in overall survival. ELIOT should be offered to selected patients at low-risk of IBTR.
Final results from a study of a blood test that can detect more than 50 types of cancer have shown that it is accurate enough to be rolled out as a multi-cancer screening test among people at higher risk of the disease, including patients aged 50 years or older, without symptoms.
NSCLC Trials Show Extended DFS With Atezolizumab, Call for Improved Implementation of Biomarker Testing
The most likely research to change practice soon from the ASCO Annual Meeting was the IMpower010 trial, which showed benefit with atezolizumab in patients with NSCLC in the adjuvant setting, though likely just in those with higher PD-L1 expression.
Data from genomic and histologic analyses in the KRYSTAL-1 study show that a diversity of on-target and off-target mechanisms can confer resistance to KRAS(G12C) inhibition and support the need for development of additional KRAS inhibitors with alternative modes of binding and different allele specificities.
This ESMO Clinical Practice Guideline provides key recommendations for managing anal cancer. The guideline covers clinical and pathological diagnosis, staging and risk assessment, treatment, follow-up and survivorship. Treatment algorithms for locoregional and advanced anal cancer are provided. Opportunities for personalised medicine in anal cancer are discussed. Recommendations were compiled by the authors based on available scientific data and the authors' collective expert opinions.
Neoadjuvant endocrine therapy (NET) is a valuable, evidence-based approach to downstaging large or locally advanced hormone receptor–positive breast cancer. Studies have shown that biomarkers such as Ki-67 and genomic assays such as Oncotype Dx may play a role in predicting tumor response to NET.
Combination Immunotherapy With IDO Inhibitors: Defining a Future Through Biomarker-Guided Patient Selection
Combined treatment with synergistic agents holds great promise in otherwise refractory malignancies; among the frontrunners in this research have been inhibitors of tryptophan conversion to kynurenine.
FDA Encourages Inclusion of Patients with Incurable Cancers in Oncology Clinical Trials Regardless of Prior Therapies
On 24 June, the FDA issued a draft guidance encouraging industry to include patients with incurable cancers (when there is no potential for cure or for prolonged/near normal survival) in cancer clinical trials, regardless of whether they have received existing alternative treatment options. Historically, many clinical trials have required that participating patients previously received multiple therapies.
ALK Mutations and Amplifications are Independent Predictors of Poorer Survival in High-Risk Neuroblastoma
In a study that examined whether the presence of an ALK alteration was associated with a poor prognosis in a large patient series treated in the prospective European high-risk neuroblastoma study, the International Society of Paediatric Oncology European Neuroblastoma Study Group (SIOPEN) found that ALK alterations are independent predictors of poorer survival.
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
Pembrolizumab is recommended as an option for untreated metastatic colorectal cancer with high microsatellite instability (MSI) or mismatch repair (MMR) deficiency in adults, only if: pembrolizumab is stopped after 2 years and no documented disease progression, and the company provides pembrolizumab according to the commercial arrangement.
The Changing Landscape in Ovarian Cancer Treatment: Shifting Toward a Neoadjuvant Approach and Away From Intraperitoneal Chemotherapy
Historically, primary cytoreductive surgery followed by chemotherapy was the standard of care for advanced (stage IIIC or IV) ovarian, fallopian tube, and primary peritoneal carcinomas. However, there are often cases when upfront surgery is not feasible or may lead to less favorable pathologic outcomes and/or increased morbidity.
Savolitinib Shows Promise in Pulmonary Sarcomatoid Carcinoma and Other METex14-positive NSCLC Subtypes
Savolitinib showed promising activity and had an acceptable safety profile in patients with pulmonary sarcomatoid carcinoma and other non-small cell lung cancer (NSCLC) subtypes positive for MET exon 14 (METex14) skipping alterations.
Highlights: Colorectal cancer screening and the future of chemoprevention, Novel immuno-oncology mechanisms and approaches in GI cancers, Rare GI cancers: updates and new clinical data, New developments in radiation oncology, The effetcts of drug interactions in GI oncology, How to improve outcomes of patients with metastatic pancreatic cancer.
ctDNA Monitoring Improves Early Relapse Detection After Treatment with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
The researchers reported in the Journal of Clinical Oncology the results from a prospective multicentre study which seeked to determine the utility of circulating tumour DNA (ctDNA) monitoring to risk stratify and assess treatment response for patients with large B-cell lymphoma undergoing chimeric antigen receptor (CAR) T-cell therapy.
ASCO Releases Rapid Guideline Recommendation Update for Certain Patients With Hereditary Breast Cancer
A new ASCO guideline update recommends offering 1 year of adjuvant olaparib to patients with high-risk early-stage HER2-negative breast cancer and germline BRCA mutations after completion of (neo)adjuvant chemotherapy and local treatment, including radiation.
At its June 2021 meeting, EMA has recommended an update to the product information for tofacitinib to include a new recommendation for its use. The EMA has concluded its review of a safety signal regarding major adverse cardiovascular events and cancer
Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual TNBC Following Neoadjuvant Chemotherapy
The study results show that platinum agents do not improve outcomes in patients with TNBC residual diseases following neoadjuvant chemotherapy, regardless of intrinsic subtype, and are associated with more severe toxicity when compared with capecitabine.
Testing for Genetic Alterations Is Key to Improving Outcomes in Metastatic Non–Small Cell Lung Cancer
Since almost two-thirds of patients with advanced nonsquamous NSCLC will have an identifiable driver mutation, we recommend that all patients with a new diagnosis of nonsquamous NSCLC undergo testing for genetic alterations with broad, panel-based, next-generation DNA and RNA sequencing.
Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO Virtual Plenary.
Study provides mechanistic link between red meat consumption and colorectal cancer development. Genetic mutations indicative of DNA damage were associated with high red meat consumption and increased cancer-related mortality in patients with colorectal cancer, according to a study published in Cancer Discovery.
On 16 June 2021, FDA approved avapritinib for adult patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated haematological neoplasm (SM-AHN), and mast cell leukaemia (MCL).
Although it's great to have new agents and combinations approved for helping our patients with cancer, some of these U.S. Food and Drug Administration (FDA) approvals are far less helpful than others.
Patritumab deruxtecan, an antibody drug conjugate consisting of a fully human monoclonal antibody to HER3 attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker, achieved clinically meaningful, durable efficacy in a phase I dose escalation and dose expansion study conducted in patients with locally advanced or metastatic EGFR-mutated NSCL cancer with prior EGFR tyrosine kinase inhibitor therapy.
W dniach 15 i 16 października 2021 r. odbędzie się, w trybie online, VII Warszawskie Seminarium UroRadioOnkologii. Wydarzenie kierowane jest do urologów, radiologów, radioterapeutów, onkologów, lekarzy rodzinnych oraz wszystkich specjalistów zainteresowanych tematyką.
Nivolumab is recommended, within its marketing authorisation, for treating unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma in adults after fluoropyrimidine and platinum-based therapy. It is recommended only if the company provides nivolumab according to the commercial arrangement.
PTChO zaprasza 24.06.21 o godz. 18.30 do udziału w webinarium "Leczenie okołooperacyjne chorych na czerniaka" organizowanym przez Fundację Polskiego Towarzystwa Chirurgii Onkologicznej pod merytorycznym patronatem PTChO i jego sekcji Akademia Czerniaka Będzie to unikalne, interaktywne spotkanie dla kilku specjalności medycznych, zajmujących się diagnostyką i leczeniem czerniaka z udziałem wielodyscyplinarnego zespołu ekspertów.
High Response Rates Observed Following KTE-X19 CAR T-Cell Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia
Treatment with KTE-X19, which is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, provided high rates of durable response together with a manageable safety profile in adult patients with relapsed and/or refractory B-cell acute lymphoblastic leukaemia.
Metronomic Capecitabine as Adjuvant Therapy Provides Compelling Evidence In Locoregionally Advanced Nasopharyngeal Carcinoma
Patients with locoregionally advanced nasopharyngeal carcinoma experienced improved failure-free survival and other survival outcomes with metronomic capecitabine as compared with patients receiving observation, according to phase III study data presented at the 2021 ASCO Annual Meeting. These findings were simultaneously published in the Lancet.
In RELATIVITY-047, nivolumab plus relatlimab demonstrated superior progression-free survival (PFS) by blinded independent central review (BICR), with more than a doubling of improvement in median PFS compared with nivolumab alone.
On 20 May 2021, the EMA adopted two positive opinions recommending changes to the terms of the marketing authorisation for the medicinal product daratumumab. New indications concern the treatment of patients with multiple myeloma and light chain amyloidosis.
Precision medicine is finally gaining traction in prostate cancer owing to advances in genetic testing. During the 2021 ASCO Annual Meeting Education Session “Application of Genomic Testing Treatment for Patients With Prostate Cancer,” experts provided an overview of the current state of genomic testing in prostate cancer.
There are currently no treatment guidelines for appendiceal cancers. In patients with appendiceal adenocarcinoma, colon cancer algorithms are typically used, while patients with resected stage III/IV goblet cell adenocarcinoma usually receive adjuvant chemotherapy.
Colorectal cancer (CRC) liver metastases develop in approximately 35% to 55% of patients during the course of their disease. Complete surgical resection of all metastases with preservation of sufficient liver function gives patients the best chance of long-term survival.
The treatment landscape for hematologic malignancies fundamentally changed following the recent approval of highly effective CAR T-cell therapies. However, multiple barriers to CAR T-cell therapy exist, including cost and toxicities.
Improved pathological complete response rates were observed in patients with resectable NSCLC treated with neoadjuvant nivolumab plus chemotherapy compared to chemotherapy alone.
New indication concerns the treatment of paediatric patients with high-risk first relapsed Philadelphia chromosome negative CD19-positive B-precursor acute lymphoblastic leukaemia (ALL).
Adjuvant chemotherapy (ACT) failed to improve survival outcomes following concurrent chemoradiation (CRT) in patients with locally advanced cervical cancer, compared with treatment with CRT alone, according to results of the phase III OUTBACK trial.
OlympiA Supports Use of Adjuvant Olaparib As a New Standard of Care for Select Patients With Early Breast Cancer
Adding a 1-year course of adjuvant olaparib following the completion of standard therapy significantly lowered the risk of disease recurrence among patients with high-risk, HER2-negative, early-stage breast cancer harboring germline BRCA mutations within the randomized phase III OlympiA trial.
As Novel Therapies for Newly Diagnosed Multiple Myeloma Emerge, Researchers Question the Value of Standard-of-Care Autologous Stem Cell Transplant
Autologous stem cell transplant continues to be the standard of care for transplant-eligible patients with newly diagnosed multiple myeloma. But studies of carfilzomib, an irreversible second-generation epoxyketone proteasome inhibitor, demonstrate that the agent is capable of inducing deep responses and high minimal residual disease.
The randomized phase III SWOG S1216 trial failed to show a significant overall survival improvement with orteronel (TAK-700) plus androgen deprivation therapy when compared with bicalutamide plus ADT in newly diagnosed men with metastatic hormone-sensitive prostate cancer.
Adjuvant pembrolizumab offered a significant and clinically meaningful improvement in disease-free survival compared with placebo in patients with locoregional renal cell carcinoma who underwent nephrectomy, according to results of the KEYNOTE-564 trial.
Pembrolizumab demonstrated continued PFS benefit, with a trend for OS benefit, as first-line therapy for patients with MSI-H mCRC, compared with chemotherapy, in the final analysis of KEYNOTE-177.
An immunotherapy target that has gained traction over the past year in early-phase trials for the management of multiple hematologic malignancies is the CD47 axis. Targeting this immunoglobulin induces activation of antitumor macrophages. This therapeutic approach appears particularly promising for hematologic malignancies.
NRG1 Fusion–positive Lung Cancers are Molecularly, Pathologically, and Clinically More Heterogeneous than Previously Thought
The goals of the eNRGy1 global multicentre registry are to characterise the features of NRG1 fusion–positive lung cancers and elucidate the clinical activity of systemic therapy in a centrally curated real-world database of patients with these rare cancers.
Several trials are underway investigating potential treatments for KIT-mutant melanoma. Patients with BRAF wild-type melanoma refractory to anti–PD-1/anti–CTLA-4 therapy have limited treatment options and developing therapies for these patients is an active area of investigation.
Approaches to Determine Whether Patients With Metastatic Non–Small Cell Lung Cancer Are Eligible for Targeted Therapy
A growing number of targeted therapies are available for metastatic NSCLC, but it is important to consider the specific mutation(s) and genetic alteration(s) in determining whether a targeted therapy is appropriate.
Bone-Protecting Agents May Be Pivotal in the Treatment of Metastatic Castration-Resistant Prostate Cancer
Newly released safety data among men with castration-resistant prostate cancer (CRPC) and bone metastases found that the addition of a bone-protecting agent (BPA) to treatment with radium 223 (Ra223) effectively reduces the risk of bone fracture.
Pimitespib, a heat shock protein 90 (HSP90) inhibitor, significantly prolonged median progression-free survival (PFS) in comparison with placebo among patients with treatment-refractory advanced gastrointestinal stromal tumor (GIST)
Central Eastern European Academy of Oncology to instytucja powołana przez przedstawicieli krajów Europy Środkowo Wschodniej by poprzez edukację poprawiać wyniki leczenia nowotworów w krajach Naszego regionu. Zapraszamy na pierwsze spotkanie w ramach nowego programu edukacyjnego w dniu 15 czerwca o godzinie 15.00.
Efficacy and Safety of Adjuvant Nivolumab for High-Risk Muscle-Invasive Urothelial Carcinoma After Radical Surgery
In the CheckMate 274 study, median disease-free survival (DFS) was significantly longer with adjuvant nivolumab than with placebo among patients with high-risk muscle-invasive urothelial carcinoma after radical surgery with curative intent.
Dose escalation in prostate cancer has been a double-edged sword. On the one hand, it leads to improved freedom from biochemical failure (FFBF), but on the other, the increased doses to normal tissues result in an increase of gastrointestinal or urogenital toxicity.
On 28 May 2021, FDA granted accelerated approval to sotorasib, a RAS GTPase family inhibitor, for adult patients with KRAS G12C ‑mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer
Collaborating on the Phase 3 AMEERA-6 study expected to be the first pivotal trial of an oral selective estrogen receptor degrader (SERD) in the adjuvant setting and will evaluate the safety and efficacy of Sanofi’s investigational amcenestrant in estrogen receptor-positive (ER+) patients who prematurely discontinue standard therapy and have high risk of disease recurrence.
Atezolizumab is recommended, within its marketing authorisation, as an option for untreated metastatic non-small-cell lung cancer (NSCLC) in adults if: their tumours have PD-L1 expression on at least 50% of tumour cells or 10% of tumour-infiltrating immune cells, their tumours do not have epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations
On 28 May 2021, FDA granted accelerated approval to infigratinib, a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
Zapraszamy do bezpłatnego udziału w konferencji on-line Akademia Onkologii Urologicznej, która poświęcona będzie postępom i standardom leczenia nowotworów układu moczowo-płciowego mężczyzny. Szczególnie wiele miejsca w trakcie wydarzenia zostanie poświęcone rakowi stercza. Nie zabraknie też tematów dotyczących raka nerki, raka pęcherza moczowego oraz nowotworów zarodkowych jądra.
A follow-up analysis of data from the Finnish cohorts of two international, randomised, double-blind, phase III studies of human papillomavirus (HPV) vaccines showed that protective HPV vaccine-induced antibody titres can be detected up to 12 years after vaccination.
Zapraszamy 10 czerwca o 18.30 do udziału w webinarium “Współczesna ścieżka diagnostyczno-terapeutyczna chorych na czerniaka – rola chirurga onkologa”. Oferujemy unikalne, interaktywne spotkanie dla kilku specjalności medycznych, zajmujących się diagnostyką i leczeniem czerniaka z udziałem wielodyscyplinarnego zespołu ekspertów.
On 20 May 2021, EMA adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product pembrolizumab. New indication concerns the first-line treatment of advanced oesophageal carcinoma or gastroesophageal junction adenocarcinoma.
Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavourable-Risk Hodgkin Lymphoma
Brentuximab vedotin (BV) + doxorubicin, vinblastine, and dacarbazine (AVD) × four cycles is a highly active and well-tolerated treatment program for ES, unfavourable-risk Hodgkin lymphoma, including bulky disease.
FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy
On May 28, 2021, FDA approved sotorasib as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy.
FDA Grants Accelerated Approval to Amivantamab-vmjw for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations
On 21 May 2021, FDA granted accelerated approval to amivantamab-vmjw, a bispecific antibody directed against epidermal growth factor (EGF) and MET receptors, for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
On 20 May 2021, EMA adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product cemiplimab. New indications concern the treatment of basal cell carcinoma and non-small cell lung cancer.
New indication concerns a combination of two drugs for the treatment of mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC).
Among patients with resected oesophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy, disease-free survival was significantly longer among those who received nivolumab adjuvant therapy than among those who received placebo.
On 20 May 2021, the FDA approved nivolumab for patients with completely resected oesophageal or gastro-oesophageal junction cancer with residual pathologic disease who have received neoadjuvant chemoradiotherapy.
New Data Raise Questions About the Role of PD-L1 Inhibition and Chemotherapy in Advanced Stage Ovarian Cancer
The addition of a PD-L1 inhibitor to combination bevacizumab and chemotherapy for women with newly diagnosed advanced stage ovarian cancer does not improve progression-free survival (PFS) compared with placebo, according to newly published data in the Journal of Clinical Oncology.
On 21 May 2021, FDA approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
In a large analysis, the association between thyroiditis and overall survival (OS) varied by tumour type, but was strongest in patients with lung cancer, possibly related to the shared developmental origin of thyroid and lung epithelia.
In final guidance published today (20 May 2021), NICE has recommended ravulizumab (Ultomiris, Alexion Pharmaceuticals) as a treatment for paroxysmal nocturnal haemoglobinuria (PNH). Draft guidance published 19 May 2021 also recommends the treatment for atypical haemolytic uraemic syndrome (aHUS).
Zapraszamy do bezpłatnego udziału w dwudniowej konferencji online dla lekarzy wszystkich specjalizacji zajmujących się diagnostyką i leczeniem nowotworów płuca. Konferencja pod kierownictwem naukowym prof. Joanny Chorostowskiej-Wynimko.
A chemotherapy-free regimen of vemurafenib and rituximab induced a durable complete response in most patients with refractory or relapsed hairy-cell leukaemia.
Genetic testing in an unselected group of women with endometrial cancer revealed actionable germline variants in cancer susceptibility genes for 10% of women, according to new research to be presented during the 2021 ASCO Annual Meeting.
Capecitabine Maintenance Therapy Improves Progression-Free Survival in Metastatic Nasopharyngeal Carcinoma
Capecitabine maintenance therapy offered substantially increased progression-free survival compared with best supportive care in metastatic nasopharyngeal carcinoma. Overall survival results are immature, although promising, and need confirmation in larger studies.
BRAVO-Feasibility Study Underscores the Challenges of a Trial Comparing BCG Versus Radical Cystectomy in High-Risk Nonmuscle Invasive Bladder Cancer
Intravesical immunotherapy with Bacillus Calmette-Guerin (BCG) and radical cystectomy are both standard treatment options for patients with high-risk nonmuscle invasive bladder cancer (HRNMIBC). However, these vastly different treatment modalities have never been formally compared in a head-to-head trial.
Results from recent clinical trials using the second-generation HIF-2α inhibitor belzutifan (MK-6482) have demonstrated the drug as a promising treatment approach for clear cell renal cell carcinoma (ccRCC).
Techniki zieleni indocyjaninowej to nowe i co raz szersze możliwości zastosowania w chirurgii nowotworów. Rok 2005 i pierwsze informacje na temat biopsji węzła wartowniczego. Dziś to w zasadzie kolejny dopuszczalny, alternatywny do radiokoloidu standard. Następne lata to odkrywanie zastosowania techniki w ocenie ukrwienia zespoleń w chirurgii przewodu pokarmowego oraz w chirurgii rekonstrukcyjnej.
No seroconversion found upon a single dose in elderly cancer patients and those treated with chemotherapy, a reason for not extending the period between the two injections.
[ 177 Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer
[177Lu]Lu-PSMA-617 compared with cabazitaxel in men with metastatic castration-resistant prostate cancer led to a higher PSA response and fewer grade 3 or 4 adverse events. [177Lu]Lu-PSMA-617 is a new effective class of therapy and a potential alternative to cabazitaxel.
Maintenance Rucaparib for Platinum-Sensitive Pancreatic Adenocarcinoma with HRD-Associated Mutations
Maintenance rucaparib is a safe and effective treatment for patients with platinum-sensitive pancreatic adenocarcinoma and germline or somatic pathogenic variants in BRCA1/2 or PALB2. The authors wrote that the results of their study provide promising evidence, complementing and furthering findings reported in the POLO study, that PARP inhibition may be an effective maintenance treatment for a broader range of patients with pancreatic adenocarcinoma
Germline mutations in BRCA1 and BRCA2 (BRCA1/2) and PALB2 are associated with high response rates to chemotherapy and PARP inhibitors. However, the frequency of mutations in BRCA1/2 and other cancer risk genes in patients with metastatic breast cancer (mBC) are not well-defined. The objective of this study was to define the frequencies of mutations in these genes among patients with mBC and to assess tumor and patient characteristics associated with the presence of mutations.
Two papers on testicular cancer from the International Germ Cell Cancer Collaborative group (IGCCCG) Update Initiative, published recently in the Journal of Clinical Oncology, underline the importance of revisiting and updating tumour classification systems.
New indication concerns combination treatment with a hypomethylating agent in adult patients with newly diagnosed AML who are ineligible for intensive chemotherapy.
NICE draft guidance published today (14 May 2021) recommends pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability (MSI) or mismatch repair (MMR) deficiency.
A 3-month duration of capecitabine and oxaliplatin (CAPOX) may be a treatment option for some patients with high-risk stage II colon cancer. This conclusion is from the latest publication of results from the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) collaboration.
Cemiplimab Outperforms Investigator’s Choice Chemotherapy in the Second-Line Setting for Recurrent/Metastatic Cervical Carcinoma
Overall survival (OS) was significantly improved with cemiplimab as compared to investigator’s choice of chemotherapy in patients with recurrent/metastatic cervical cancer and progression after first-line platinum-based treatment, according to interim findings from a phase III study presented at the ESMO Virtual Plenaries.
There are no general contraindications to receiving the mRNA vaccines or Ad26.COV2.S vaccine for patients with cancer. Considerations for patients receiving specific therapies are below. In patients undergoing cytotoxic chemotherapies, lymphocyte activity is suppressed; therefore, the immune response to vaccines is expected to be perturbed.
Prof. Thomas Powles of the Barts Cancer Institute, Queen Mary University of London, UK and BISCAY study investigators combined durvalumab with relevant targeted therapies in biomarker-selected chemotherapy-refractory advanced urothelial cancer populations.
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%
Cemiplimab monotherapy significantly improved overall survival and progression-free survival compared with chemotherapy in patients with advanced non-small-cell lung cancer with PD-L1 of at least 50%, providing a potential new treatment option for this patient population.
Przesyłamy Ankietę dotyczącą stosowanych technik w szeroko pojętej Chirurgii Raka Gruczołu Piersiowego. Jest to przygotowanie do kolejnego spotkania, III Konsensusu Polskiego Towarzystwa Chirurgii Onkologicznej. Aktualizacja wytycznych i zasad właściwego postępowania w codziennej praktyce klinicznej dotyczącej raka piersi to ważny problem.
On 5 May 2021, the FDA granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastro-oesophageal junction (GEJ) adenocarcinoma.
European Cancer Organisation Calls for Urgent Action as One Million Cancer Cases are Undiagnosed in Europe Due to Covid-19
Nearly one million Cancer cases in Europe are being missed due to Covid-19, according to new data published today by the European Cancer Organisation. The findings coincide with the launch of campaign to urge the public, cancer patients, policymakers and healthcare professionals to ensure Covid-19 does not continue to undermine the fight against Cancer.
Most Cases of Venous Thromboembolic Events, Elevated Aminotransferases, and Interstitial Lung Disease Are Manageable in Patients Receiving Adjuvant Abemaciclib for Early Breast Cancer
Adverse events associated with abemaciclib were characterised in patients participating in the phase III open-label monarchE study. Findings from a safety analysis of data from the phase III monarchE study were presented at the ESMO Breast Cancer Virtual Congress 2021.
Occurrence of Interstitial Lung Disease Related to Trastuzumab Deruxtecan in Patients with HER2-positive Metastatic Breast Cancer
Drug–related interstitial lung disease (ILD) occurred in less than 16% of patients with HER2-positive metastatic breast cancer following treatment with trastuzumab deruxtecan (T-DXd) at the approved dose (5.4 mg/kg), and the majority of these cases were Grade 1 or 2.
Identification of Potential Biomarkers for Clinical Benefit Following Dual Neoadjuvant Anti-HER2 Blockade in HER2-positive/HR-negative Early Breast Cancer
Specific RNA expression signatures were indicators of pathological complete response (pCR) and better invasive disease-free survival (iDFS) after 12 weeks of de-escalated neoadjuvant pertuzumab plus trastuzumab with or without paclitaxel in patients with HER2-positive, hormone receptor (HR)-negative early breast cancer.
Risk of Distant Recurrence of ER-Positive Breast Cancer in Premenopausal Women According to 70-Gene Risk Signature
Long-term 20-year follow-up of premenopausal patients with oestrogen receptor (ER)-positive breast cancer and stratification by the 70-gene Risk Signature suggested that patients at high risk of distant disease recurrence derive significant benefit from goserelin, while patients at low risk have greater benefit with tamoxifen.
PTMN zaprasza na konferencję online w dniach 20-22 maja 2021. Usłyszymy krótkie wykłady przedstawicieli naszego Towarzystwa, którzy omówią postępy w różnych kierunkach rozwoju medycyny nuklearnej. Szczegóły i rejestracja na stronie medycynanuklearna-online.pl Udział jest bezpłatny.
Neoadjuvant Pertuzumab/Trastuzumab Demonstrates Long-Term Cardiac Safety in HER2-Positive Breast Cancer
Patients with stage IIA to III HER2-positive breast cancer demonstrated high rates of event-free survival (EFS) and a low occurrence of cardiac events at 5 years after receiving neoadjuvant/adjuvant pertuzumab plus trastuzumab with standard anthracycline-containing therapies.
Reassuring Results Observed with Shorter Duration of Adjuvant Trastuzumab in HER2-positive Early Breast Cancer
Long-term findings presented at the ESMO Breast Cancer Virtual Congress 2021 showed that similar disease-free survival (DFS) benefit was obtained with 9 weeks versus one-year of adjuvant trastuzumab in patients with HER2-positive early breast cancer and low to intermediate risk for disease recurrence, which may reassure patients who must discontinue adjuvant trastuzumab earlier than one year due to cardiac adverse events.
The RAD51-IF Test Is Feasible for Assessment of the Functional Status of Homologous Recombination Repair in TNBC Tumours
Functional homologous repair deficiency (HRD), as defined by a RAD51-low score, emerged as an indicator of patient outcome and response to carboplatin in triple negative breast cancer (TNBC) or PARP inhibitors, according to findings from two studies presented at the ESMO Breast Cancer Virtual Congress 2021.
First results from a phase II study evaluating atezolizumab plus carboplatin presented at the ESMO Breast Cancer Virtual Congress 2021 demonstrated clinical benefit in patients with metastatic invasive lobular breast cancer (ILC), particularly in patients with triple negative ILC.
C-KP did not result in improved efficacy in any reasonably sized biomarker subgroup. These findings from a biomarker analysis of data from the phase III KAITLIN study were presented at the ESMO Breast Cancer Virtual Congress 2021.
Lung cancer is a disease of adults with lungs. It is not a disease of adults who smoke. It is not a disease of men. The risk factors for lung cancer (beyond smoking, radon and asbestos exposures, and age) remain poorly understood.
Education Session Navigates Strategies in Finding the Right Dose, From Phase I Trials to Clinical Practice
A key objective in first-in-human studies of oncology agents is to establish a maximum tolerated dose that can be used in phase II trials. The maximum tolerated dose approach, which has largely dominated the dose-finding paradigm in oncology, was predominantly based on cytotoxic agents.
ASCO has approved new recommendations for appropriate dosing of systemic anticancer agents in obese adults with cancer. The guideline update was based on evidence collected from a systematic review of the literature published between 2010 and 2020, regarding dosing of chemotherapy, immunotherapy, and targeted therapies in obese adults with cancer. The original guideline published in 2012 focused on chemotherapy agents alone.
ASCO convened an Expert Panel to conduct a systematic review of the literature on neoadjuvant therapy for breast cancer and provide recommended care options. A total of 41 articles met eligibility criteria and form the evidentiary basis for the guideline recommendations.
Apalutamide Plus ADT Provides Significant Improvement in Overal Survival and Delays Onset of Progression in mCSPC
The final analysis of the TITAN demonstrates that the long-term use of apalutamide plus androgen deprivation therapy (ADT) provided significant improvement in overall survival (OS) and delayed onset of progression despite almost 40% crossover from placebo to apalutamide after the study was unblinded.
Do końca maja bieżącego roku można przesyłać prace, które zostaną zaprezentowane podczas V Kongresu Onkologii Polskiej. Kongres odbędzie się w dniach 20-23 października 2021 r. we Wrocławiu.
A group of US investigators found a substantial decrease in the use of minimally invasive surgery, robotic or laparoscopic, for cervical cancer after publication of the results of the Laparoscopic Approach to Cervical Cancer (LACC) Trial. This reduction in clinical practice is mainly found among academic centres.
EORTC Director General Dr Denis Lacombe spoke on “Quality assurance of clinical trial structures: harmonisation of technical requirements to support multinational institutional collaborations in next-generation clinical trials” at the European Cancer Research Summit held in Porto, Portugal
On 22 April 2021, the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Abiraterone KRKA (abiraterone acetate), intended for the treatment of metastatic prostate cancer. Abiraterone KRKA is a generic of Zytiga, which has been authorised in the EU since 2011.
In the German Hodgkin Study Group HD17 trial, we investigated whether radiotherapy can be omitted without loss of efficacy in patients who have a complete metabolic response after receiving two cycles of of escalated doses of eBEACOPP plus two cycles of ABVD chemotherapy (2.0 + 2.0).
Personalisation of follow-up care is needed to address varying health burdens in breast cancer patients
As breast cancer becomes a largely curable disease, with more than 70% of women surviving at least 10 years after diagnosis across most of Europe thanks to early detection and treatment, the quality of life after cancer has become an important aspect of the patient journey – one that may be inadequately addressed with current standards of follow-up.
The free information source is designed to help people living with cancer and caregivers recognize symptoms of blood cell deficiencies caused by cancer or chemotherapy — and increase engagement with their oncology care team about management and support.
On 22 April 2021, the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product azacitidine, intended for the maintenance treatment of patients with acute myeloid leukaemia (AML).
EORTC Gastrointestinal Cancer Group launches its Young Investigators & Early Career Investigators’ Program for 2021
The EORTC Gastrointestinal Group invites to apply for the 2021-2023 term of the EORTC GI Group’s Young Investigators & Early Career Investigators’ Program. This program offers a scholarship for a 3 investigators from institutions which are providing a certain standard of cancer care and research, with active participation in clinical or preclinical/translational research activities.
On 22 April 2021, the European Medicines Agency adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product selumetinib, intended for the treatment of paediatric patients with neurofibromatosis type 1 (NF1) plexiform neurofibromas.
This ESMO Clinical Practice Guideline provides key recommendations for managing cancer-related cachexia. It covers screening, assessment and multimodal management of cancer cachexia. All recommendations were compiled by a multidisciplinary group of experts. Recommendations are based on available scientific data and the author’s expert opinion.
On 23 April 2021, the FDA granted accelerated approval to loncastuximab tesirine-lpyl, a CD19-directed antibody and alkylating agent conjugate, for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.
A new ASCO guideline provides the first evidence-based recommendations for the management of salivary gland malignancies (SGMs) that's been developed by a multidisciplinary Expert Panel. The guideline offers recommendations on preoperative evaluation, diagnostic and therapeutic surgical procedures, radiotherapy, systemic therapy, follow-up evaluations, and recurrent metastatic disease.
On 22 April 2021, the European Medicines Agency (EMA) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal products nivolumab and ipilimumab. New indication concerns treatment of unresectable malignant pleural mesothelioma.
A hypofractionated schedule of 55 Gy in 20 fractions is non-inferior to 64 Gy in 32 fractions with regard to both invasive locoregional control and toxicity, and is superior with regard to invasive locoregional control. 55 Gy in 20 fractions should be adopted as a standard of care for bladder preservation in patients with locally advanced bladder cancer.
Sacituzumab Govitecan Prolongs Survival in Relapsed or Refractory Metastatic Triple Negative Breast Cancer
Sacituzumab govitecan, a first-in-class, Trop-2–directed antibody–drug conjugate, showed in the ASCENT study a significant benefit among patients with relapsed or refractory metastatic triple negative breast cancer (TNBC) in terms of progression-free survival (PFS) and overall survival (OS) as compared with standard of care chemotherapy.
New indication concerns adjuvant treatment in patients with non-small cell lung cancer (NSCLC) whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
The European Cancer Organisation’s HPV Action Network is calling for the establishment of an HPV Vaccine Tracker to be hosted by the European Centre for Disease Prevention and Control (ECDC). This monitoring system would provide invaluable information about EU Member States’ progress towards meeting the Beating Cancer Plan’s goal of eliminating the cancers caused by HPV.
Azacitidine Plus Eprenetapopt Induces High Clinical Responses, Molecular Remissions in TP53-Mutant AML and MDS
Mutations in TP53, which are largely predictive of poor overall prognosis in patients with cancer, are reported in approximately 10% to 20% of patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Overall, most patients with TP53 mutations generally lack good treatment options to control their disease.
The optimal radiotherapy dose for indolent non-Hodgkin lymphoma is uncertain. We aimed to compare 24 Gy in 12 fractions (representing the standard of care) with 4.0 Gy in two fractions (low-dose radiation).
Sentinel Lymph Node Biopsy Navigated Neck Dissection Is Not Inferior to Elective Neck Dissection in Early Oral Cancer
A study performed in 16 institutions in Japan shows that sentinel lymph node biopsy (SLNB)-navigated neck dissection is not inferior and it is less invasive than elective neck dissection in patients with early stage oral cavity squamous cell carcinoma (OCSCC).
After the successful application of cellular therapies in hematologic malignances, investigators have focused their efforts on identifying new targets and expanding the use of this technology to solid tumors.
Six-Year APHINITY Data Bolster Use of Adjuvant Pertuzumab, Trastuzumab, and Chemotherapy in HER2-Positive, Node-Positive Breast Cancer
The most recent planned analysis of the 4,805-patient trial showed that adding pertuzumab to adjuvant trastuzumab and chemotherapy reduced the risk of recurrence or death by 24% among the overall population with either lymph node–positive or high-risk lymph node–negative disease.
A study publishedin the January 2021 issue of the Journal of Clinical Oncology (JCO) found that the PD-1 inhibitor nivolumab has a survival benefit over docetaxel at 5 years post-treatment in previously-treated advanced non–small cell lung cancer (NSCLC).
Experts share their perspectives on how the five phase III clinical trials presented during the 2020 Plenary Session shaped clinical practice over the last year and how they will continue to do so in years to come.
Tipifarnib Demonstrates Encouraging Efficacy in Patients with Recurrent and/or Metastatic HNSCC with HRAS Mutations
In a phase II study conducted in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) with mutant HRAS variant allele frequency ≥20%, treatment with tipifarnib produced an objective response rate (ORR) of 55%, median progression-free survival (PFS) of 5.6 months and a median overall survival (OS) of 15.4 months.
A brand new oral treatment for an incurable blood cancer has today (21 April 2021) been recommended for NHS use by NICE. Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated chronic lymphocytic leukaemia (CLL).
The European Code of Cancer Practice, translated in many languages, is a citizen and patient-centred manifesto of the core requirements for good clinical cancer practice, in order to improve outcomes for all of Europe’s cancer patients.
NICE draft guidance provides first in Europe access to new treatment option for advanced breast cancer
NICE has published draft guidance recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund (CDF) for treating a type of breast cancer called HER2 positive breast cancer which can’t be surgically removed or which has spread to other parts of the body.
FDA Grants Accelerated Approval to Melphalan Flufenamide for Relapsed or Refractory Multiple Myeloma
On 26 February 2021, the FDA granted accelerated approval to melphalan flufenamide in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD-38 directed monoclonal antibody.
Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group
In this Policy Review, the Bone Working Group of the International Myeloma Working Group updates its clinical practice recommendations for the management of multiple myeloma-related bone disease.
FDA Approves Nivolumab in Combination with Chemotherapy for Metastatic Gastric Cancer and Oesophageal Adenocarcinoma
On 16 April 2021, the FDA approved nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, gastro-oesophageal junction cancer, and oesophageal adenocarcinoma. Efficacy was evaluated in CHECKMATE-649 (NCT02872116) study.
The IGCCCG Update Model Allows Improved and More Granular Individual Prognostic Assessment in Metastatic Non-Seminomatous Germ Cell Tumours
A new web-based calculator based on the results of the International Germ Cell Cancer Collaborative Group (IGCCCG) Update analysis allows improved and more granular individual prognostic assessment in patients with metastatic non-seminomatous germ cell tumours (NSGCT) and can help to shape strategies for future clinical trials.
Udostępniamy Państwu pełny materiał z webinarium poświęconego leczeniu chorych z pierwotnymi i wtórnymi (przerzutowymi) nowotworami otrzewnej. Mamy nadzieję, wspólnie z autorami wszystkich wykładów, że przedstawione przykłady przyczynią się do częstszego leczenia nowotworów otrzewnej metodą CRS + HIPEC.
In clinical oncology, fibroblast growth factor receptor (FGFR) screening usually refers to testing a patient's tumor tissue for activating DNA mutations in the FGFR2 or FGFR3 gene that can potentially be targeted with a FDA – approved FGFR inhibitor.
Percentage of Cancer Patients Who Are Eligible for and Respond to Genome-Targeted Therapy Modestly Increased Over Time
A new analysis from US show that response to genome-targeted therapy increased from 2.73% in 2006 to 7.04% in 2020. Most of the increase in response was seen prior to 2018, and most of the increase in eligibility after 2018.
Although impressive progress has been made on the non–small cell lung cancer (NSCLC) landscape, with U.S. Food and Drug Administration (FDA)–approved therapies for a multitude of molecular alterations, the advancements in small cell lung cancer (SCLC) have been less robust.
On 13 April 2021, the FDA granted accelerated approval to sacituzumab govitecan for patients with locally advanced or metastatic urothelial cancer (mUC) who previously received a platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor.
Zapraszamy serdecznie w imieniu organizatorów na Konferencję „Debaty Rak Prostaty”, która odbędzie się 22.05.2021 roku (sobota), w trybie online. Wydarzenie kierowane jest do urologów, onkologów, radioterapeutów, lekarzy rodzinnych oraz wszystkich specjalistów zainteresowanych tematyką.
W imieniu organizatorów serdecznie zapraszamy na interdyscyplinarną konferencję naukową “Wyzwania współczesnej diagnostyki genetycznej i onkohematologii dziecięcej”. Celem wydarzenia jest poszerzenie wiedzy z zakresu diagnostyki genetycznej oraz onkohematologii.
On 6 April 2021, the FDA approved a new dosage regimen of 500 mg/m2 as a 120-minute intravenous infusion every two weeks (Q2W) for cetuximab for patients with K-Ras wild-type, EGFR-expressing metastatic colorectal cancer (mCRC) or squamous cell carcinoma of the head and neck (SCCHN).
Journal of the National Comprehensive Cancer Network publishes new research which suggests that baseline brain imaging should be considered in most patients with metastatic kidney cancer. Study finds 4% of patients with metastatic renal cell carcinoma developed asymptomatic brain metastases, which correlated to poorer outcomes.
Pozytywna opinia AOTMiT dotycząca refundacji olaparybu w leczeniu raka jajnika, jajowodów i otrzewnej
6 kwietnia 2021 roku Rada Przejrzystości przy AOTMiT wydała pozytywną opinię w sprawie objęcia refundacją leków zawierających substancję czynną olaparibum w zakresie terapii podtrzymującej u pacjentów z zaawansowanym rakiem jajnika, jajowodu lub otrzewnej.
On 7 April 2021, the FDA granted regular approval to sacituzumab govitecan for patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.
The European Society for Clinical Nutrition and Metabolism (ESPEN) launched its guideline on clinical nutrition in cancer as an app version for smartphones and tablets. The app is available for download for iOS and Android. A web-based version is available at guidelines.espen.org for free.
This textbook provides a practically applicable resource for understanding the surgical oncology management of pancreatic cancer. It discusses relevant aspects of anatomy and pathophysiology along with the latest diagnostic techniques. Insightful descriptions are then provided detailing how to perform critical surgical procedures when treating these patients.
Copanlisib-Rituximab Combination Cuts Lymphoma Progression or Death by Nearly Half in CHRONOS-3 Trial
A combination of copanlisib and rituximab led to a 48 percent reduction in the risk of disease progression or death compared with placebo and rituximab in patients with relapsed indolent non-Hodgkin lymphoma, according to data from the phase III trial CHRONOS-3, presented during Week 1 of the virtual AACR Annual Meeting 2021.
Men who had a high genetic risk of developing prostate cancer were less likely to develop a lethal form of the disease if they maintained a healthy lifestyle, according to results presented during Week 1 of the virtual AACR Annual Meeting 2021.
Liquid Biopsy Augments MRI for Predicting Response to Neoadjuvant Treatment in Patients With Breast Cancer
A liquid biopsy test to assess plasma cell-free DNA (cfDNA) integrity could improve the accuracy of magnetic resonance imaging (MRI) for predicting the achievement of complete response among patients with locally advanced breast cancer who had received neoadjuvant chemotherapy, according to results presented during Week 1 of the virtual AACR Annual Meeting 2021.
Personalized Cancer Vaccine Given After Adjuvant Therapy Safe, Shows Early Efficacy in Multiple Tumor Types
Treatment with the neoantigen cancer vaccine PGV-001 following standard-of-care adjuvant therapy was well tolerated and showed potential clinical benefit in patients with diverse tumor types with high risk of recurrence, according to results from a phase I clinical trial presented during Week 1 of the virtual AACR Annual Meeting 2021.
Unselected Autologous Tumor Infiltrating Lymphocyte Therapy Shows Early Promise in Patients With Metastatic Melanoma
Treatment with unselected autologous tumor infiltrating lymphocytes (TILs) showed early clinical efficacy among patients with advanced melanoma, according to results presented during Week 1 of the virtual AACR Annual Meeting 2021.
Bispecific Fusion Protein Tebentafusp Significantly Improves Overall Survival in Patients With Metastatic Uveal Melanoma
Compared with available standard therapies, including immune checkpoint inhibitors, treatment with the bispecific fusion protein tebentafusp nearly halved the risk of death among patients with metastatic uveal melanoma, according to results of a phase III clinical trial presented during Week 1 of the virtual AACR Annual Meeting 2021.
Neoadjuvant Nivolumab plus Chemotherapy Increased Pathological Complete Response Rate in CheckMate-816 Lung Cancer Trial
Adding nivolumab to chemotherapy as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC) produced significant improvement of pathological complete response rate to 24 percent, compared with 2.2 percent in the chemotherapy alone arm, with the combination treatment leading to no increase in overall toxicity or delays to surgery, according to data from the phase III trial CheckMate-816, presented during Week 1 of the virtual AACR Annual Meeting 2021.
On 25 March 2021, the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product duvelisib, intended for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) and refractory follicular lymphoma (FL).
Japanese researchers reported on 1 April 2021 in The Lancet Gastroenterology & Hepatology findings from a randomised, double-blind, placebo-controlled study with a two-by-two factorial design, conducted in 11 centres, that low-dose aspirin safely suppressed the recurrence of colorectal polyps larger than 5 mm in patients with familial adenomatous polyposis (FAP).
PARP inhibitors are a potential effective treatment option for patients with BRCA-associated cancers, including pancreatic adenocarcinoma (PDAC). The POLO study was the first biomarker-driven phase III trial to show an improvement in progression-free survival in PDAC.
Surgery is a key component of cancer care and 80% of cancer patients will require some form of surgical intervention during the course of their disease. It is estimated that by the year 2030, 45 million surgical procedures will be required. Additionally, in some less-developed regions of the world, surgery may be the only viable treatment option for several reasons.
On 26 March 2021, FDA approved idecabtagene vicleucel for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. This is the first FDA-approved cell-based gene therapy for multiple myeloma.
Sarcomas need biomarkers perhaps more than any other group of malignancies due to their unpredictability, controversy around systemic therapy, and questions surrounding patient selection for immunotherapy.
Ahead of a meeting today with the EU Commissioner for Health and Food Safety, the European Cancer Organisation (E.C.O.) has published a new consensus paper conveying the critical challenges for the cancer workforce in the context of implementing Europe’s Beating Cancer Plan.
Adjuvant Nivolumab Prolongs DFS in Patients with Resected Osophageal or Gastroesophageal Junction Cancer
In CheckMate 577 study conducted among patients with resected oesophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy, adjuvant therapy with nivolumab was associated with a significantly longer disease-free survival (DFS) than placebo.
Focal Boost to the Intraprostatic Tumour in External Beam Radiotherapy for Patients With Localised Prostate Cancer
This study investigates whether focal boosting of the macroscopic visible tumour with external beam radiotherapy increases biochemical disease-free survival (bDFS) in patients with localised prostate cancer.
Polskie Towarzystwo Chirurgii Onkologicznej, Sekcja Onkologiczna Polskiego Towarzystwa Dermatologicznego oraz Polskie Towarzystwo Patologów opracowało wspólnie kartę-drogowskaz „Pacjent ze zmianą barwnikową. Postępowanie diagnostyczne dla dermatologów i chirurgów wraz z kartą konsultacyjną pacjenta”.
On 25 March 2021, European Medicines Agency’s adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product enzalutamide. New indication concerns the treatment of metastatic hormone-sensitive prostate cancer in combination with androgen deprivation therapy.
NCCN będzie współpracować z specjalistami z Polski w zakresie tworzenia polskich zaleceń postępowania diagnostyczno-terapeutycznego w onkologii
Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie, National Comprehensive Cancer Network i Alliance for Innovation podpisały umowę o współpracy, dzięki której eksperci z NCCN podzielą się swoją wiedzą i międzynarodowym doświadczeniem w opracowaniu zaleceń postępowania diagnostyczno-terapeutycznego w onkologii.
Zaproszenie na webinarium „Zabiegi cytoredukcyjne i HIPEC w leczeniu chorych z nowotworami otrzewnej”
Zapraszam Państwa na Webinarium poświęcone leczeniu chorych z pierwotnymi i wtórnymi (przerzuty) nowotworami otrzewnej. Prezentacje będą miały formę omówienia leczenia wybranych przypadków medycznych „case reports” - dr hab. n. med. Tomasz jastrzębski, prof. nadzw.
Combination Immunotherapy and BRAF/MEK Inhibitor Therapy for BRAFV600-Mutated Advanced Melanoma: Are We There Yet?
Triplet therapy provides a new treatment option for patients with advanced BRAF-mutated melanoma, but is limited by the lack of survival benefit and increased toxicity.
Delayed irAEs Occur in a Small Subset of Patients with Melanoma, but Often High Grade and Difficult to Manage
An analysis published on 30 March 2021 in the Annals of Oncology, shows that delayed immune-related adverse events (irAEs) occur in a small subset of patients with melanoma. However, delayed irAEs are often high grade and difficult to manage, frequently requiring extended course of systemic corticosteroids or additional immunosuppression and can lead to death.
The ADAURA trial showed a 46% absolute risk reduction of recurrence at 2 years with osimertinib, but the trial has several limitations, including disease-free survival as a surrogate endpoint.
An analysis based on a review of the recent FDA approval of pembrolizumab in patients with treatment-refractory cancers and a tumour mutational burden (TMB) greater than 10 mutations per megabase, found that the overall survival (OS) benefit was decreased in several tumour types and after re-evaluation according to stratification by other criteria.
Doctors who oversee cancer clinics say that new patients are arriving for treatment with more advanced disease than before the COVID-19 pandemic, according to a new survey from the American Society for Radiation Oncology (ASTRO).
FDA approved pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced oesophageal or gastro-oesophageal (tumours with epicenter 1 to 5 centimeters above the gastro-oesophageal junction) carcinoma who are not candidates for surgical resection or definitive chemoradiation.
W imieniu organizatorów serdecznie zapraszamy na interdyscyplinarną konferencję naukową “Wyzwania współczesnej diagnostyki genetycznej i onkohematologii dziecięcej”. Celem wydarzenia jest poszerzenie wiedzy z zakresu diagnostyki genetycznej oraz onkohematologii.
We report the clinical outcomes of a randomised trial comparing prophylactic whole-pelvic nodal radiotherapy to prostate-only radiotherapy (PORT) in high-risk prostate cancer. Prophylactic pelvic irradiation for high-risk, locally advanced prostate cancer improved BFFS and DFS as compared with PORT, but OS did not appear to differ.
New indication concerns first-line treatment of patients with metastatic NSCLC whose tumours have high PD-L1 expression.
Safety Analysis Shows that Durvalumab Treatment After SBRT Is Feasible in Patients with Early Stage NSCLC
Results from the ASTEROID study with durvalumab after stereotactic body radiotherapy in patients with early stage non-small cell lung cancer.
Mutations in Circulating Tumor Cells May Predict Clinical Outcomes in Patients with Metastatic Castrate-resistant Prostate Cancer
Various genetic alterations in circulating tumor cells (CTCs) were associated with clinical outcomes and resistance to hormone therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC), according to results published in Molecular Cancer Research, a journal of the American Association for Cancer Research.
Despite sound rationale that patients with platinum sensitive non-small cell lung cancer (NSCLC) should also be sensitive to poly (ADP-ribose) polymerase inhibitors (PARPi), olaparib maintenance did not improve survival in a small under-enrolled phase II study. These findings were presented at the European Lung Cancer Virtual Congress 2021.
Zapraszamy w imieniu organizatorów na Konferencję „Debaty Rak Nerki”, która odbędzie się 24 kwietnia 2021 roku (sobota), w trybie online. Wydarzenie kierowane jest do urologów, onkologów, nefrologów, radioterapeutów, lekarzy rodzinnych oraz wszystkich specjalistów zainteresowanych tematyką.
Clinical activity with a second drug inhibiting KRASG12C confirms its role as a therapeutic target in patients with advanced non-small-cell lung cancer (NSCLC) harbouring this mutation, according to results from a study with the KRASG12C inhibitor adagrasib reported at the European Lung Cancer Virtual Congress 2021.
Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer
Updated results from the phase III KEYNOTE-407 study reported at the European Lung Cancer Virtual Congress 2021 demonstrated that survival and response rates remained improved with pembrolizumab plus chemotherapy over placebo plus chemotherapy in treatment-naive patients with metastatic squamous non-small cell lung cancer (NSCLC).
Computed tomography (CT) and/or magnetic resonance imaging (MRI) demonstrated that 39% of patients diagnosed with stage IV non-small cell lung cancer (NSCLC) presented with de novo brain metastases during the COVID-19 pandemic, higher than historic rates, and many of these patients were asymptomatic for brain metastases.
A large comprehensive analysis of patient-specific alterations of the anaplastic lymphoma kinase (ALK) gene occurring in non-small cell lung cancer (NSCLC) reported at the European Lung Cancer Virtual Congress 2021 provided additional insight into the landscape of ALK alterations that may guide treatment of NSCLC.
A retrospective analysis of patients with non-small cell lung cancer (NSCLC) identified potentially targetable alterations in the phosphoinositide-3-kinase (PI3K) pathway that were not mutually exclusive to mutations in other pathways, according to findings presented at the European Lung Cancer Virtual Congress 2021.
The incidence of brain metastasis at diagnosis in patients with non-small cell lung cancer (NSCLC) harbouring driver mutations was high, according to findings presented at the European Lung Cancer Virtual Congress 2021. However, these patients achieved similar outcomes with treatment as patients without brain metastases.
CAR T-cell therapies are cultivating new and promising care approaches for patients with multiple myeloma. Many hematologic malignancies, including myeloma, are currently incurable and linked to low overall survival rates. CAR T-cell interventions may continue improving treatment plans, symptom management, and health outcomes in the multiple myeloma space.
Between 10% and 15% of patients with non–small cell lung cancer (NSCLC) have brain metastases at the time of diagnosis, with some 25% to 50% developing intracranial disease over their disease course, representing nearly half of all patients with central nervous system (CNS) metastases. The incidence is expected to increase as survival in advanced NSCLC continues to improve.
W imieniu organizatorów mamy przyjemność zaprosić na X Edycję Ogólnopolskiej Konferencji Naukowej „Wejrzenie w nowotworzenie”. Jej celem jest przybliżenie uczestnikom mechanizmów molekularnych odpowiedzialnych za powstawanie chorób nowotworowych, a także prezentacja postępów w ich diagnostyce i leczeniu.
The 690,000 cases of cancer caused worldwide each year by HPV (human papillomavirus) are among the easiest of all cancers to prevent. However, the actions so far taken in terms of both policy and practice by health systems in many European states have neither matched the scale of the problem nor seized the opportunities for disease prevention potentially offered by vaccination and screening.
Surviving glioblastoma? EORTC Brain Tumour Group explores the factors that contribute to long-term survival
Glioblastomas represent almost 50% of malignant primary brain tumors in adults, and range among the most lethal cancer types. Approximately three in 100,000 people a year are diagnosed with a glioblastoma. Due to the aggressive nature of this tumor, which invades the brain by infiltration and destroys healthy brain tissue, glioblastomas lead to a significantly reduced life span.
Zapraszamy na webinarium poświęcone leczeniu chorych z pierwotnymi i wtórnymi (przerzuty) nowotworami otrzewnej. Prezentacje będą miały formę omówienia leczenia wybranych przypadków medycznych („case reports”), obejmujących śluzaka rzekomego otrzewnej, przerzuty do otrzewnej raka żołądka, raka jajnika, raka jelita grubego a także nowotworów wieku dziecięcego.
Better understanding of specific risk factors associated with poor COVID-19 outcomes may help guide clinical management in these patients. Leveraging detailed information from almost 5,000 cancer patients with COVID-19, researchers from an international CCC19 consortium evaluated the hypothesis that specific demographic characteristics, clinical factors, and laboratory measurements are associated with severity of COVID-19.
A new second line triple therapy is to be offered to NHS patients in England with multiple myeloma after NICE recommended its use. Clinical trial evidence shows that carfilzomib with lenalidomide and dexamethasone gives longer periods of remission and people live longer, compared with the current second line treatment lenalidomide plus dexamethasone.
FDA Grants Accelerated Approval to Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma
On 5 March 2021, the US Food and Drug Administration (FDA) granted accelerated approval to axicabtagene ciloleucel for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. Approval in FL was based on a single-arm, open-label, multicentre study (ZUMA-5; NCT03105336).
High Tumour Mutation Burden Fails to Predict Response to Immune Checkpoint Inhibitors Across All Cancer Types
According to a group of researchers led by Dr Daniel McGrail of MD Anderson Cancer Center in Houston, TX, US, who analyzed data from patient tumours included in The Cancer Genome Atlas (TCGA), their analysis failed to support the use of high tumour mutation burden (TMB-H) as a biomarker for treatment with immune checkpoint inhibitors (ICIs) in all tumour types.
Treatment for advanced kidney cancer has undergone an impressive improvement in recent years due to the development of targeted therapies against VEGF, a key driver of angiogenesis, or mTOR pathways and immunotherapy. Those treatments have been sequentially offered to patients demonstrating an increase in overall survival (OS).
EMA’s Safety Committee Has Concluded That the Benefits of Ifosfamide Solutions for Infusion Continue to Outweigh Risks
The European Medicines Agency (EMA) announced on 12 March 2021 that its Pharmacovigilance Risk Assessment Committee (PRAC) has concluded that the benefits of ifosfamide solutions for infusion continue to outweigh their risks in the treatment of different types of cancers, including various solid tumours and lymphomas.
Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC)
Radical surgery via total mesorectal excision might not be the optimal first-line treatment for early-stage rectal cancer. An organ-preserving strategy with selective total mesorectal excision could reduce the adverse effects of treatment without substantially compromising oncological outcomes. We investigated the feasibility of recruiting patients to a randomised trial comparing an organ-preserving strategy with total mesorectal excision.
In an updated integrated analysis of three phase I or II clinical studies ALKA-372-001, STARTRK-1, and STARTRK-2, comprising more patients and a longer follow-up than the primary analysis, entrectinib continued to demonstrate a high level of clinical benefit for patients with ROS1 fusion–positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
Long-term results from MINDACT trial confirm importance of gene expression signature in choosing breast cancer patients who can be spared chemotherapy
The decision on whether or not to give chemotherapy after breast cancer surgery is always a difficult one. Because the treatment can have serious side effects, some of them long-term, there is sometimes a risk that its use may do more harm than good. The MINDACT (EORTC 10041/BIG3-04) study, a multicentre, randomised phase 3 clinical trial, aimed to provide an answer to this question.
On 10 March 2021, the US Food and Drug Administration (FDA) approved tivozanib, a kinase inhibitor, for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
This textbook provides a practically applicable resource for understanding the surgical oncology management of pancreatic cancer. It discusses relevant aspects of anatomy and pathophysiology along with the latest diagnostic techniques. Insightful descriptions are then provided detailing how to perform critical surgical procedures when treating these patients.
Leading cancer and infectious disease experts analyze latest data and FDA approvals to create evidence-based expert consensus recommendations for both treatment and prevention of COVID-19 for people with cancer.
Clinical utility of whole-genome sequencing demonstrated for the genomic evaluation of patients with acute myeloid leukaemia or myelodysplastic syndromes.
Zarząd Polskiego Towarzystwa Ginekologii Onkologicznej uważa, że korzyści z małoinwazyjnej chirurgii w porównaniu z laparotomią w przypadku nowotworów trzonu macicy są oczywiste i uzasadniają wybór tej formy terapii jako metody z wyboru. Zastosowanie chirurgii laparoskopowej czy robotowej, u chorych na raka szyjki macicy powinna być szeroko wykorzystywana jedynie w ramach badań klinicznych lub guzów o średnicy do 2 cm.
Konferencja „Urologia post COVID-19” odbędzie się 20.03.2021 roku (sobota), w trybie online. Wydarzenie kierowane jest do urologów, onkologów, nefrologów, radiologów, ginekologów, lekarzy rodzinnych oraz wszystkich specjalistów zainteresowanych tematyką. Podczas wydarzenia omówione zostaną między innymi: wnioski z analizy opóźnień w wykonywaniu zabiegów operacyjnych.
On 3 March 2021, the US Food and Drug Administration (FDA) granted regular approval to lorlatinib for patients with metastatic non-small cell lung cancer (NSCLC) whose tumours are anaplastic lymphoma kinase (ALK)-positive, detected by an FDA-approved test.
Immune checkpoint inhibitors (ICIs) are the standard of care for eligible patients with mRCC. However, a significant number of patients will not benefit from the initial ICI treatment because of primary resistance, and some will relapse after a period of response, a state known as acquired or secondary resistance.
Molecular profiling in the field of gastrointestinal (GI) cancers is precision medicine at its finest, according to physician-scientist Rachna T. Shroff, MD, MS, chief of GI Medical Oncology at the University of Arizona Cancer Center and member of the ASCO Daily News Expert Panel.
NEOSTAR Results Indicate that Neoadjuvant Nivolumab Plus Ipilimumab Enhances Pathologic Responses in Operable NSCLC
Findings from the randomised phase II NEOSTAR study indicate that neoadjuvant treatment with nivolumab plus ipilimumab enhances pathologic responses, tumour immune infiltrates and immunologic memory in patients with operable non-small cell lung cancer (NSCLC).
Results of new study from Mass General Hospital Cancer Center, Harvard Medical School, and Dana-Farber Cancer Institute underscore the need for the development and testing of nutrition and fitness interventions, as muscle quality significantly correlates with symptom burden, healthcare utilization, and survival.
EMA Recommends Granting a Marketing Authorisation for Generic Abiraterone for the Treatment of Metastatic Prostate Cancer
On 25 February 2021, the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Abiraterone Accord, intended for the treatment of metastatic prostate cancer.
The European Society for Clinical Nutrition and Metabolism (ESPEN) launched its guideline on clinical nutrition in cancer as an app version for smartphones and tablets. The app is available for download for iOS and Android. A web-based version is available at guidelines.espen.org for free.
Significant Benefits of Nivolumab Plus Cabozantinib Over Sunitinib in Previously Untreated Advanced RCC
In CheckMate 9ER study among patients with previously untreated advanced renal-cell carcinoma (RCC), nivolumab plus cabozantinib had significant benefits over sunitinib in terms of progression-free survival (PFS), overall survival (OS), and the likelihood of objective response.
Cancer survivors had a greater risk of reduced ambulatory function, which was associated with an increased risk of death, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
Combination of cabozantinib and nivolumab is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma
Novel approaches to treating prostate and bladder cancers are renewing hope for patients with genitourinary (GU) malignancies. At the same time, the field is being further energized by the recent U.S. Food and Drug Administration (FDA) approval of several new agents.
Results of Pivotal Study with BCMA Specific CAR T-Cell Therapy in Patients With Refractory and Relapsed Multiple Myeloma
Idecabtagene vicleucel, a B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T-cell therapy induced responses in a majority of heavily pretreated patients with refractory and relapsed multiple myeloma.
Despite improvements in treatment and early detection, the incidence of breast cancer is rising, with prevention of modifiable risk factors remaining the best strategy for reducing mortality.
Twice daily poziotinib dosing improved the adverse event profile; early results showed retained anti-tumour activity.
Clinical benefit of FGFR inhibition is stronger in patients with an FGFR fusion or mutation compared to FGFR amplification.
Tumour Signatures Defined by Next Generation Sequencing Are Linked to Clinical Response in Breast Cancer
Endogenous and exogenous mutational processes driven by abnormal DNA editing, mutagens or age-related DNA alterations over the history of a malignant tumour provide an individual tumour signature
Prelliminary data with IL-12 mRNA administered by intratumoural injection in combination with intravenous durvalumab
The Risk of irAEs After Immune Checkpoint Inhibitor Therapy May Not Be Elevated in Patients with Autoimmune Disease
Many cancer patients with autoimmune disease are excluded from studies of immune checkpoint inhibitors due to hypothesis of the association of this treatment with immune-related adverse events.
The patterns of PD-L1 mRNA expression in plasma-derived exosomes at baseline corresponded to response to atezolizumab plus nab-paclitaxel and survival in patients with triple negative breast cancer
Characterisation of Toxicity Profiles of Immune and Molecularly Targeted Agents in Phase I and II Studies
Overall, more adverse events were reported with targeted therapies than with immunotherapy.
It is intended for the treatment of recurrent or advanced dMMR/MSI-H endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen.
The efficacy of CDK4/6 inhibitors in combination with standard endocrine therapy for HR+/HER2−negative early breast cancer has been actively explored in several clinical trials, including monarchE, PALLAS, and PENELOPE-B.
ASCO has issued a new guideline on the clinical management of dyspnea in adult patients with advanced cancer.1 Dyspnea—or breathlessness—is a common and distressing symptom affecting upwards of 70% of patients with advanced cancer.
Advanced breast cancer, defined for the purposes of this discussion as breast cancer that has spread to distant metastatic sites, is generally understood to be an incurable condition. Patients are, however, often curious about the role of breast surgery in the management of their cancer.
Final Results of the Collaborative EORTC/Intergroup Randomised Phase III Study of Adjuvant Imatinib in Localised GIST
After 9.1 years of follow-up, a trend toward better long-term imatinib failure-free survival in imatinib treated patients was observed in high-risk subgroup.
Approval concerns the treatment of patients with tumours without EGFR, ALK or ROS1 aberrations.
Tisagenlecleucel outcomes in relapsed or refractory DLBCL and follicular lymphoma.
EMA Pharmacovigilance Risk Assessment Committee Advice on Safety-Related Aspects of the Gene Therapy
As part of its advice on safety-related aspects to other European Medicines Agency (EMA) committees, the Pharmacovigilance Risk Assessment Committee (PRAC) discussed important safety information for Strimvelis, Venclyxto and Zolgensma.
Amplification of HER2 is seen in approximately 15% to 20% of breast cancers and was associated with an inferior prognosis until the introduction of HER2-targeted therapies.1 Since then, disease-related outcomes such as disease-free survival (DFS), progression-free survival (PFS), and OS have improved remarkably.
Efficacy and Safety of Adjuvant Pertuzumab, Trastuzumab and Chemotherapy After 6 Years Median Follow-Up in the APHINITY Study
Cardiac safety is confirmed with longer follow-up after adjuvant dual anti-HER2 treatment for node-positive, HER2-positive early breast cancer.
ASCO and Ontario Health Publish Joint Update on Guideline for Targeted Therapy in NSCLC With Driver Alterations
ASCO and Ontario Health (Cancer Care Ontario) have jointly published an update1 to the 2017 ASCO guideline2 regarding systemic therapy recommendations for stage IV non–small cell lung cancer (NSCLC) with driver alterations.
The International Neoadjuvant Melanoma Consortium reported the results of a pooled analysis that aimed to determine the relationship between pathological complete response (pCR) and clinical outcomes with neoadjuvant anti-PD1 immunotherapy and BRAF/MEK targeted therapy in patients with clinical stage III melanoma.
The Oncotype DX recurrence score (RS) has been shown to provide both predictive information about the potential benefit of chemotherapy as well as prognostic information about recurrence risk.
Neoadjuvant Therapy for Pancreatic Cancer: An Optimal Management Approach for All Stages That Needs Further Prospective and Randomized Evaluation
Recent advances in the treatment of pancreatic adenocarcinoma (PAC) have improved the overall survival (OS) of patients with all stages of disease.1 However, despite curative intent treatment, the majority of patients experience recurrence. An improved understanding of the patterns of recurrence and strategies to mitigate local, regional, and distant recurrence will help maximize OS.
What is the role of immunotherapy in treating non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations?
Two large case–control studies provide important information on the risk of breast cancer and cancer types that is associated with several genes and their variants
Based on results from the SOLO2/ENGOT-ov21 trial, could maintenance PARP inhibitor (PARPi) therapy ever be safely discontinued in patients with relapsed ovarian cancer and a BRCA mutation?
In patients with EGFR-mutant advanced lung cancer who have developed acquired resistance to EGFR tyrosine kinase inhibitors (TKIs), could chemotherapy plus a TKI with stereotactic body radiotherapy (SBRT) be used for persistent lesions?
Obiecujące wyniki badań nad radioterapią skojarzoną ze środkami farmaceutycznymi nadzieją dla chorych na glejaka
Glejak wielopostaciowy jest jednym z najbardziej śmiertelnych i najtrudniejszych do leczenia nowotworów mózgu. Radioterapia jest częścią standardowego schematu leczenia glejaka wielopostaciowego i często pomaga przedłużyć czas przeżycia pacjentów. Jednak pomimo postępów w medycynie czas przeżycia pacjentów z glejakiem nie poprawił się znacząco w ciągu ostatnich dwóch dekad.
Ranking of Molecular Alterations in HNSCC According to ESCAT Classification Provides Targeted Therapy Information
Using the European Society for Medical Oncology (ESMO) Scale for Clinical Actionability of molecular Targets (ESCAT) investigators were able to rank the level of evidence of recurrent actionable molecular alterations found in head and neck squamous cell carcinoma (HNSCC) to aid in the prioritisation of treatment.
PROfound Shows Significant Antitumor Activity With Olaparib for mCRPC in Patients With DNA Repair Mutations
An updated gene-by-gene analysis of DNA repair mutations in patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase III PROfound study found that patients with BRCA alterations had the most significant antitumor activity on olaparib , highlighting the potential overall survival (OS) benefit of genetic testing for all patients with high-risk mCRPC.
ModraDoc006/Ritonavir Offers Promising Therapeutic Option for mCRPC, Convenient Approach Amid COVID-19 Pandemic
ModraDoc006, a novel oral docetaxel formulation, has advantages as a convenient, oral, and better-tolerated potential therapeutic option for patients with metastatic castration-resistant prostate cancer (mCRPC) when combined with ritonavir.
CheckMate-9ER: Patient-Reported Outcomes Show Significantly Improved Quality-of-Life Benefit of Novel Doublet for Advanced Renal Cell Carcinoma
The CheckMate-9ER phase III trial revealed significantly improved patient-reported quality-of-life outcomes with first-line nivolumab plus cabozantinib compared to sunitinib for patients with advanced renal cell carcinoma (RCC), potentially matching the superior clinical efficacy of the novel doublet.
Circulating tumor DNA (ctDNA) and tissue-based genomic profiling had high levels of agreement in patients with metastatic renal cell carcinoma (mRCC), according to a new study to be presented during the 2021 Genitourinary Cancers Symposium (Abstract 347). Furthermore, ctDNA can detect changes to genomic profiles over time and potentially help guide treatment.
On 28 January 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product pembrolizumab (Keytruda).
Two new studies to be presented during the 2021 Genitourinary Cancers Symposium demonstrate the utility of genomic analysis of circulating cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) in advanced prostate cancer, offering noninvasive methods to identify targetable genetic mutations and thus potentially guide treatment with PARP inhibition.
On 3 February 2021, the US Food and Drug Administration (FDA) granted accelerated approval to tepotinib (Tepmetko, EMD Serono Inc.) for adult patients with metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
Importantly, although the MR-LINAC may result in more precise (and safer) and higher-dose radiation plans, what ultimately matters is demonstrated improvement in clinical outcomes. Single institutional series from early MR-LINAC adopters show promising results regarding survival and toxicity rates,9-11 and there is now an open multi-institutional prospective trial: Stereotactic MRI–guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer.
The European Medicines Agency (EMA) announced on 29 January 2021 that Roche Registration GmbH withdrew its application for the use of atezolizumab (Tecentriq) to treat metastatic urothelial cancer in combination with platinum-based therapy in patients who had not been treated before. The company withdrew the application on 8 January 2021.
For patients with metastatic bladder cancer who are ineligible for cisplatin-containing chemotherapy and have high PD-L1 expression, atezolizumab and pembrolizumab are approved by the U.S. Food and Drug Administration (FDA) as first-line treatment. Multiple assays, which differ in terms of the antibodies used, cells scored, and cutoff values, are commercially available to assess PD-L1 expression. Because of the lack of standardization across these different tests, there is ambiguity surrounding the preferred assay for patients with metastatic bladder cancer.
On 28 January 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product selinexor (Nexpovio) intended for the treatment of relapsed and refractory multiple myeloma.
On 28 January 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product pemigatinib, intended for the second-line treatment of locally advanced or metastatic cholangiocarcinoma characterised by fusion or rearrangements of fibroblast growth factor receptor 2 (FGFR2).
ASCO has released a new guideline regarding the use of neoadjuvant chemotherapy, endocrine therapy, and targeted therapy in breast cancer.
An ASCO Expert Panel has endorsed an American Society for Radiation Oncology (ASTRO) guideline on radiation therapy (RT) for small cell lung cancer (SCLC), stating the recommendations in the ASTRO guideline “are clear, thorough, and based upon the most relevant scientific evidence” available.
The management of pancreatic ductal adenocarcinoma (PDAC) has undergone a major paradigm shift in the last 30 years. Before the 1990s, surgical resection was the main treatment modality, with high morbidity and slim chances for cure. In 1985, the Gastrointestinal Tumor Study Group demonstrated the benefit of adjuvant 5-fluorouracil-based chemoradiotherapy (CRT) with almost doubled median overall survival.
Wiadomo, że regularne stosowanie aspiryny przynosi wyraźne korzyści w zmniejszaniu zachorowalności na raka jelita grubego u dorosłych w średnim wieku, ale wiąże się również z pewnym ryzykiem, takim jak krwawienie z przewodu pokarmowego. W tym kontekście pojawia się ważne pytanie - kiedy dorośli powinni zacząć przyjmować profilaktycznie aspirynę i jak długo to robić?
An early look at the data from the phase III OPERA (Organ Preservation in Early Rectal Adenocarcinoma) trial suggests that most patients with cT2, cT3a, or cT3b rectal cancer who develop a clinical complete response to treatment, may safely forego surgery after neoadjuvant chemoradiotherapy (CRT) plus an additional radiotherapy boost without compromising the chance of cure.
A blood test for early detection of colorectal adenomas and cancer shows promise for improving survival and prevention of colorectal cancer (CRC) by enabling the stratification of patients for screening or post-polypectomy surveillance colonoscopy, according to a new study.
Updated results from IMbrave150 underscore the benefit of frontline Atezolizumab plus Bevacizumab in unresectable HCC
Results from the phase III IMbrave150 trial collected over a median of 15.6 months continue to support the superiority of combined treatment with atezolizumab plus bevacizumab over sorafenib in the first-line setting among individuals with unresectable hepatocellular carcinoma (HCC).
Analysis of the PDAC immune microenvironment sheds light on the effects of chemotherapy, informing future treatment strategies
An exploratory study reveals that neoadjuvant chemotherapy alters the immune microenvironment within pancreatic ductal adenocarcinoma (PDAC), and different chemotherapy regimens appear to exert different effects. Digging into the details of these data may help researchers determine how best to utilize chemotherapy in PDAC to maximize its efficacy.
FDA approved the combination of nivolumab and cabozantinib as first-line treatment for patients with advanced renal cell carcinoma (RCC). Efficacy was evaluated in CHECKMATE-9ER (NCT03141177), a randomised, open-label study in patients with previously untreated advanced RCC.
Szpitale stosujące dobre praktyki żywienia klinicznego - rusza II edycja programu certyfikacji żywieniowej
Polskie Towarzystwo Żywienia Pozajelitowego, Dojelitowego i Metabolizmu (POLSPEN) rozpoczyna II edycję programu Szpital Dobrej Praktyki Żywienia Klinicznego – Leczenie przez żywienie. W pierwszej edycji udział wzięły 64 szpitale z całej Polski. Rada ekspertów, po przeprowadzeniu certyfikacji nagrodziła 27 szpitali. Pokazuje to, że jest jeszcze wiele obszarów do poprawy w zakresie żywienia klinicznego w polskim szpitalnictwie. Inicjatywa programu ma na celu upowszechnić w szpitalach dobre praktyki żywienia klinicznego i dać szansę pacjentom na poprawę stanu odżywienia podczas walki z chorobą.
Cancer and Aging Research Group-Breast Cancer score, which they derived by combining eight clinical and geriatric variables, was developed to classify elderly patients with early breast cancer into low, intermediate, and high risk for developing grade 3-5 chemotherapy toxicity.
Młodzi polscy lekarze i studenci medycyny zrzeszeni w organizacji RÉSONNEZ zapraszają na cykl webinarów poświęconych radiologii. Łącznie odbędzie się 12 sesji obejmujących tematykę m.in. diagnostyki radiologicznej raka piersi, RTG klatki piersiowej, radiologii interwencyjnej czy rozpoznawania złamań na obrazach rentgenowskich.
FDA approved fam-trastuzumab deruxtecan-nxki for adult patients with locally advanced or metastatic HER2-positive gastric or gastro-oesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
Findings from the American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange (GENIE) registry show that KRASG12C somatic mutations are present in non-small cell lung cancer (NSCLC), colorectal cancer, appendiceal and small bowel cancers, and cancers of unknown primary site, with a mutation frequency of 3 to 14%.
Serial analysis of circulating tumor DNA (ctDNA) after surgery can identify patients with stage I-III colorectal cancer (CRC) at high risk for recurrence. A prospective study demonstrated that ctDNA can signal relapse far better than carcinoembryonic antigen (CEA) surveillance and earlier than standard radiological imaging.
Patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC) who received neoadjuvant therapy with modified FOLFIRINOX (mFOLFIRINOX) had an 18-month overall survival (OS) rate of 66.4% in a prospective phase II study conducted by the National Clinical Trials Network (Abstract 377). This rate exceeded the prespecified historical control of 50%, establishing mFOLFIRINOX as efficacious.
Updated 3-year results confirm the benefit of adjuvant S-1 plus Docetaxel for stage III gastric cancer
The randomized controlled GC-07 trial conducted by the Japan Clinical Cancer Research Organization (JACCRO) previously met the primary endpoint at the second interim analysis by demonstrating a recurrence-free survival (RFS) advantage with use of S-1 plus docetaxel versus S-1 alone after D2 gastrectomy for stage III gastric cancer.1 As a result, the study was terminated as per the recommendation of the independent data and safety monitoring committee well before the overall survival (OS) data had fully matured.
Leczenie zaawansowanego raka jajnika inhibitorami PARP, nowo zarejestrowanymi w Unii Europejskiej do stosowania po pierwszej linii leczenia, jest szansą na terapię tą innowacyjną grupą leków nie tylko chorych z mutacją w genach BRCA, ale i pozostałej większości pacjentek. Badania wykazały wydłużenie czasu wolnego od progresji choroby u wszystkich pacjentek chorych na raka jajnika, które odpowiedziały na chemioterapię pochodnymi platyny.
Adding FGFR2b-targeted therapy to chemotherapy improved clinical outcomes for patients with advanced gastric-esophageal cancers in phase II study
The phase II FIGHT study lays the groundwork for introducing another targeted therapy besides trastuzumab as a first-line treatment option for selected patients with advanced gastric or gastroesophageal junction adenocarcinoma (Abstract 160).
Adjuvant therapy with Oxaliplatin added to Fluoropyrimidine improves survival in patients with MSI/dMMR stage III colon cancer
The ACCENT database analysis supports flouropyrimidine plus oxaliplatin as standard-of-care adjuvant treatment for patients with MSI/dMMR stage III colon cancer.
Findings from the observational DELIVER trial sponsored by the Japan Clinical Cancer Research Organization showed that patients with advanced gastric cancer who responded to nivolumab treatment had a more diverse gut microbiome compared with patients who did not respond to the immunotherapy (Abstract 161).
Newly developed RSClin provides prognostic information in HR-positive, HER2-negative early breast cancer
The online RSClin tool incorporating clinical-pathological data and the results of a 21-gene recurrence score (RS) was able to estimate the risk of distant recurrence (DR) and the benefit from adjuvant chemotherapy in specific patients with early breast cancer. The development and validation of this tool were outlined in an article appearing on 11 December 2020 in the Journal of Clinical Oncology.
Chemotherapy administered for the first diagnosed testicular cancer reduces the risk of metachronous contralateral testicular cancer occurrence
Patients aged less than 30 years upon diagnosis of testicular cancer and those treated with surgery only are at higher risk of developing a metachronous contralateral (second) germ cell testicular cancer, according to a recent article published in the Journal of Clinical Oncology.
Palbociclib plus Endocrine therapy does not improve PFS over Capecitabine in HR-positive, HER2-negative aromatase inhibitor resistant metastatic breast cancer
Although patients with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative, aromatase inhibitor resistant metastatic breast cancer maintained quality of life (QoL) for a longer time following treatment with palbociclib plus either exemestane or fulvestrant than capecitabine, those receiving chemotherapy demonstrated improved progression-free survival (PFS) and higher response rates compared with the palbociclib-treated patients.
Circulating tumor DNA detection post-surgery foreshadows disease relapse in patients with early colorectal cancer
Prospective data from the ongoing TRACC (Tracking Mutations in Cell Free Tumour DNA to Predict Relapse in Early Colorectal Cancer) trial in the United Kingdom support the prognostic utility of circulating tumor DNA (ctDNA) detection for heralding disease recurrence in patients with stage II/III colorectal cancer.
In a multicentre, prospectively collected study in UK among operable patients with oesophageal cancer, the Oesophageal Cancer Classification and Molecular Stratification (OCCAMS) Consortium investigators demonstrated that the presence of ctDNA in post-operative plasma is strongly associated with cancer recurrence.
Management of rectal cancer needs a multidisciplinary approach to determine and deliver the most appropriate therapy for each patient. Short-course radiation followed by chemotherapy showed that complete pathologic response rates were possible for some patients. In addition, induction with mFOLFIRINOX therapy followed by chemoradiotherapy also afforded pathologic complete response rates higher than those seen historically. Is it then reasonable to consider the watch-and-wait strategy for those patients who desire organ preservation?
FDA approved selinexor in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Efficacy of selinexor in combination with bortezomib and dexamethasone was evaluated in the BOSTON study (KCP-330-023, NCT03110562), a randomised (1:1) open-label, multicentre, active comparator-controlled study in patients with RRMM who had previously received at least one and at most three prior therapies.
Patient selection and sequencing therapeutics for microsatellite instability–high, mismatch repair–deficient metastatic colorectal cancer
KEYNOTE-177 is the largest trial to date looking at checkpoint inhibitor immunotherapy (IO) with PD-1 inhibitor compared with chemotherapy in patients with MSI-high, mismatch repair (MMR)–deficient mCRC. Despite overall positive survival outcomes favoring IO, the Kaplan-Meier curve for the first 6 months of progression-free survival (PFS) highlights a subgroup of patients with MSI-high disease that progresses rapidly on IO monotherapy.
FDA approved the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist, relugolix, (ORGOVYX, Myovant Sciences, Inc.) for adult patients with advanced prostate cancer. Efficacy was evaluated in HERO (NCT03085095), a randomised, open label study in men requiring at least one year of androgen deprivation therapy with either prostate cancer recurrence following radiation or surgery or newly diagnosed castration-sensitive advanced prostate cancer.
Naukowcy z SWOG Cancer Research Network, grupy badań klinicznych finansowanej przez National Cancer Institute (NCI), wykazali, że połączenie trzech leków - irynotekanu, cetuksymabu i wemurafenibu - jest skuteczniejsze i zapewnia dłuższy czas wolny od nawrotu choroby u pacjentów z przerzutowym rakiem jelita grubego w porównaniu do pacjentów leczonymi połączeniem irynotekanu i cetuksymabu.
FDA approved osimertinib for adjuvant therapy after tumour resection in patients with non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. Efficacy was demonstrated in a randomised, double-blind, placebo-controlled study (ADAURA, NCT02511106).
FDA approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. Efficacy was evaluated in SOPHIA (NCT02492711), a randomised, multicentre, open-label study of 536 patients with IHC 3+ or ISH-amplified HER2-positive metastatic breast cancer who had received prior treatment with other anti-HER2 therapies.